As we all gear up for EIS busy season we look at the two main reasons why the Parkwalk Opportunities EIS Fund is set to be the largest EIS fund in the market again this tax year, currently over 50% larger than any other EIS Fund.
Deployment
Over the last 5 plus years we have consistently invested clients’ subscriptions within 12 months.
“Parkwalk has access to a high level of quality deal flow”Allenbridge, October 2019
For example, an investor who subscribed into the Parkwalk EIS Fund this time last year (i.e. November 2018) has been fully invested into the following deals within 12 months (an equal amount into each company):
Congenica – £23m series B investment alongside Digital Health China and CIC
Mogrify – $16m series A investment alongside Ahren Innovation Capital
Paragraf – £12.8m series A investment alongside IQ Capital and Amadeus
Oxbotica – £14m series A investment alongside IP Group and AXA
PredictImmune – £10m series B investment alongside CIC and BGF
Our investment pipeline continues to be strong, and with environmental, social and governance (“ESG”) factors becoming an ever-increasing focus for investors, we continue to invest in cutting edge technology that results in global postive impact.
Track Record
Parkwalk was set up 10 years ago to invest in the distinct asset class of UK university spin outs, and over that decade we have built up a leading network (e.g. universities and co-investors) that provides a quality deal pipeline which has resulted in attractive returns.
“Parkwalk has developed a good exit record compared to the rest of the EIS market”
Micap, October 2019
All exits (up and down) have delivered an IRR of 36.5% excl. tax reliefs (44% incl. EIS). And we are one of the few EIS funds that publish performance on its website – see here.
Have any questions on the Fund?
If you’d like to find out more, or if you would like to find out how you can access the research reports, please contact Parkwalk team on 020 7759 2285 or email [email protected]
